GeneCopoeia Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus
GeneCopoeia’s Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus products are designed to produce a specially packaged variant of standard lentivirus that replaces VSV-G envelope glycoprotein with the Spike (S) protein.
The company’s spike-pseudotyped lentivirus can be used for several applications, such as: vaccine development for the SARS-CoV-2 virus; studying the efficacy and mechanism of neutralising antibodies against the SARS-CoV-2 virus; development of antiviral therapeutic agents; and studying the mechanism of virus-receptor interaction.
In addition to lentiviral particles, GeneCopoeia also offers a SARS-CoV-2 Spike Protein Pseudotyped Lentivirus Particle Kit that includes all required reagents: Lentifect SARS-CoV-2 Spike protein-pseudotyped lentiviral particles; Lentifect Standard VSV-G lentiviral particles; and the company’s ACE2-expressing HEK293T cell line.
For more information: https://www.genecopoeia.com/product/lentifect-sars-cov-2-spike-pseudotyped-lentivirus/.
Phone: 02 4575 0309
Microbiologics UV-BioTAG QC microorganisms for quality control testing
UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...
ProSci Incorporated ferroptosis antibodies
ProSci Incorporated's range of ferroptosis antibodies includes AIFM2, NCOA4, PEX3, PEX10,...
BioClean-D Coverall with Hood and Integrated Boots – Sterile S-BDFC
Sterile coveralls act as a barrier, preventing particles, dust, microbes and other contaminants...